A phase 1/2 trial of SHR-3276 in advanced solid tumours, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.
A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors is a phase 1/2 interventional study registered as NCT06643754 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 115 participants planned, started 2024-12-10 and due to reach its primary completion in 2027-12-30. Interventions recorded: SHR-3276.
Shares Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.